» Articles » PMID: 26553810

Hepatotoxicity of High Affinity Gapmer Antisense Oligonucleotides is Mediated by RNase H1 Dependent Promiscuous Reduction of Very Long Pre-mRNA Transcripts

Abstract

High affinity antisense oligonucleotides (ASOs) containing bicylic modifications (BNA) such as locked nucleic acid (LNA) designed to induce target RNA cleavage have been shown to have enhanced potency along with a higher propensity to cause hepatotoxicity. In order to understand the mechanism of this hepatotoxicity, transcriptional profiles were collected from the livers of mice treated with a panel of highly efficacious hepatotoxic or non-hepatotoxic LNA ASOs. We observed highly selective transcript knockdown in mice treated with non-hepatotoxic LNA ASOs, while the levels of many unintended transcripts were reduced in mice treated with hepatotoxic LNA ASOs. This transcriptional signature was concurrent with on-target RNA reduction and preceded transaminitis. Remarkably, the mRNA transcripts commonly reduced by toxic LNA ASOs were generally not strongly associated with any particular biological process, cellular component or functional group. However, they tended to have much longer pre-mRNA transcripts. We also demonstrate that the off-target RNA knockdown and hepatotoxicity is attenuated by RNase H1 knockdown, and that this effect can be generalized to high affinity modifications beyond LNA. This suggests that for a certain set of ASOs containing high affinity modifications such as LNA, hepatotoxicity can occur as a result of unintended off-target RNase H1 dependent RNA degradation.

Citing Articles

The evolution and application of RNA-focused small molecule libraries.

Taghavi A, Springer N, Zanon P, Li Y, Li C, Childs-Disney J RSC Chem Biol. 2025; .

PMID: 39957993 PMC: 11824871. DOI: 10.1039/d4cb00272e.


Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.

Ruchi R, Raman G, Kumar V, Bahal R Expert Opin Drug Discov. 2024; 20(1):63-80.

PMID: 39653607 PMC: 11823135. DOI: 10.1080/17460441.2024.2440095.


A review of the complex interplay between chemoresistance and lncRNAs in lung cancer.

Alnefaie G J Transl Med. 2024; 22(1):1109.

PMID: 39639388 PMC: 11619437. DOI: 10.1186/s12967-024-05877-2.


Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.

Khuu A, Verreault M, Colin P, Tran H, Idbaih A Cells. 2024; 13(22).

PMID: 39594617 PMC: 11592788. DOI: 10.3390/cells13221869.


Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system.

Moazami M, Rembetsy-Brown J, Sarli S, McEachern H, Wang F, Ohara M Mol Ther. 2024; 32(12):4401-4417.

PMID: 39460376 PMC: 11638874. DOI: 10.1016/j.ymthe.2024.10.024.


References
1.
Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen J, Orum H . The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia. 2011; 25(4):638-47. DOI: 10.1038/leu.2010.322. View

2.
You Y, Moreira B, Behlke M, Owczarzy R . Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res. 2006; 34(8):e60. PMC: 1456327. DOI: 10.1093/nar/gkl175. View

3.
Jackson A, Linsley P . Noise amidst the silence: off-target effects of siRNAs?. Trends Genet. 2004; 20(11):521-4. DOI: 10.1016/j.tig.2004.08.006. View

4.
Jackson A, Burchard J, Schelter J, Chau B, Cleary M, Lim L . Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006; 12(7):1179-87. PMC: 1484447. DOI: 10.1261/rna.25706. View

5.
van Poelgeest E, Swart R, Betjes M, Moerland M, Weening J, Tessier Y . Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis. 2013; 62(4):796-800. DOI: 10.1053/j.ajkd.2013.02.359. View